Skip to main content

Table 3 Correlation of ALDH1 with other prognostic markers

From: Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Variable

Total No (%)

ALDH1 (+) No (%)

P-value

Total

119 (100)

56 (47)

 

Age

  

0.100

 >50

67 (56)

25 (37)

 

 ≤50

52 (44)

31 (59)

T stage

   

 T1

22 (18)

9 (40)

 

 T2

78 (65)

38 (49)

 

 T3

19 (17)

8 (42)

0.985

Nodal status

   

 Positive

96 (81)

46 (50)

 

 Negative

23 (19)

8 (38)

0.455

Histological type

   

 IDC

108 (88.5)

52 (48)

 

 ILD

11 (11.5)

4 (36)

0.537

Pathological grade

   

 1 or 2

46 (39)

22 (48)

 

 3

73 (61)

34 (46)

0.395

Breast cancer subtype

   

 Luminal A

24 (20)

10 (41)

 

 Luminal B

49 (40)

20 (41)

 

 HER2

17 (14)

10 (59)

 

 TN

29 (24)

16 (55)

0.431

Ki67 (N = 106)

   

 >20%

68 (64)

29 (58)

 

 ≤20%

38 (36)

21 (42)

0.311

Surgery

   

 Mastectomy

56 (47)

21 (37)

 

 BCS

63 (53)

35 (55)

0.066

Response

   

 pCR

26 (22)

6 (23)

 

 Non-pCR

93 (78)

50 (54)

0.007

  1. ALDH1, aldehyde dehydrogenase-1; pCR, pathologic complete response; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; TN, triple negative.